Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma

Table 2 Glypican-3 as molecule-target for hepatocellular carcinoma immunotherapy

Group	Name	Species	Epitopes	Verifying/applying
Antibody	M18D04/19B11	Mouse	N-terminal (aa: 25-358)	Basic studies
	A1836A	Mouse	N- terminal	Basic studies
	GPC3-C02	Mouse	C- terminal	Basic studies
	GC33	Mouse	C-terminal (aa: 524-563)	Preclinical trial studies
	hGC33	Human	C- terminal (aa: 524-563)	Clinical trial-II
	HS20	Human	Heparan sulfate chain	Preclinical trial
	sGPC3	Human	—	Preclinical trial
Vaccines	GPC3298-306	Mouse	298-306 peptide	Clinical trial-II
	GPC3144-152	Mouse	144-152 peptide	Clinical trial-II
miRNA	miR-219-5p	Human	—	In vitro or in vivo studies
	miR-520c-3p	Human	—	In vitro studies
	miR-1271	Human	—	In vitro studies
shRNA	GPC3 shRNA	Human	—	In vitro or in vivo studies
siRNA	GPC3 siRNA	Human	—	In vitro or in vivo studies

GPC-3: Glypican-3; aa: Amino acid; miR: MicroRNA; shRNA: Small hairpin RNA; siRNA: Small interfering RNA.